-
Dyadic International, Inc. (DYAI) Misses Q3 EPS by 1c
-
H.C. Wainwright Assumes Dyadic International (DYAI) at Buy
-
Dyadic receives milestone payments from Proliant and Inzymes partnerships
-
Sidoti Events, LLC's Virtual September Small-Cap Conference
-
Sidoti Events, LLC's Virtual September Small-Cap Conference
-
Sidoti Events, LLC's Virtual September Small-Cap Conference
-
Sidoti Events, LLC's Virtual September Small-Cap Conference
-
Craig-Hallum Starts Dyadic International (DYAI) at Buy
-
Dyadic International, Inc. (DYAI) Reports Q2 Loss of $0.06
-
Dyadic prices public offering of 6.05 million shares
-
Dyadic International, Inc. (DYAI) Rebrands as Dyadic Applied BioSolutions
-
Dyadic International, Inc. (DYAI) Announces Leadership Change
-
Dyadic International, Inc. (DYAI) Reports Q1 Loss of $0.07
-
Dyadic International, Inc. (DYAI) Files for 840K Share Offering by Selling Stockholders
-
Dyadic International, Inc. (DYAI) Misses Q4 EPS by 13c
-
Dyadic International (DYAI) Provides Business Update
-
H.C. Wainwright Reiterates Buy Rating on Dyadic International (DYAI)
-
Dyadic International, Inc. (DYAI) Tops Q3 EPS by 6c
-
Dyadic International (DYAI) Provides Alternative Proteins Business Update
-
Dyadic International, Inc. (DYAI) Reports In-Line Q2 EPS
-
H.C. Wainwright Reiterates Buy Rating on Dyadic International (DYAI)
-
Dyadic International (DYAI) and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership
-
Dyadic to Interview with Bloomberg TV on Friday, January 31, 2020

